BURDEN OF BRAIN METASTASES (BM) IN ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Pan, X. [1 ]
Kwon, C. S. [2 ]
Garib, S. A. [2 ]
Forsythe, A. [2 ]
Lin, H. M. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Purple Squirrel Econ, New York, NY USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN22
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [1] EPIDEMIOLOGICAL, CLINICAL AND HUMANISTIC BURDEN AMONG ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) PATIENTS TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)
    Pan, X.
    Kwon, C. S.
    Garib, S. A.
    Forsythe, A.
    Lin, H. M.
    VALUE IN HEALTH, 2019, 22 : S56 - S56
  • [2] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [3] Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors
    Wu, Yanyu
    Ren, Kaili
    Wan, Yin
    Lin, Huamao M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (06) : 1418 - 1427
  • [4] SYSTEMATIC LITERATURE REVIEW (SLR) OF SEQUENCING OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Barrows, S. M.
    Wright, K.
    Copley-Merriman, C.
    Kaye, J. A.
    Chioda, M. D.
    Wiltshire, R.
    Torgersen, K. M.
    Masters, E. T.
    VALUE IN HEALTH, 2018, 21 : S49 - S50
  • [5] ECONOMIC BURDEN OF BRAIN METASTASES IN PATIENTS WITH ALK plus NON-SMALL CELL LUNG CANCER IN CHINA
    Xiao, F.
    Peng, X.
    Li, R.
    Luan, L.
    Le, H.
    Dong, P.
    VALUE IN HEALTH, 2024, 27 (12) : S99 - S99
  • [6] Economic burden in patients with ALK plus non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
    Lin, Huamao M.
    Pan, Xiaoyun
    Hou, Peijie
    Huang, Hui
    Wu, Yanyu
    Ren, Kaili
    Jahanzeb, Mohammad
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (08) : 894 - 901
  • [7] COMPARATIVE EFFICACY OF FIRST-LINE ALK-INHIBITORS IN ALK plus LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
    Haddad, Philip
    Hammoud, Dalia
    Gallagher, Kevin
    NEURO-ONCOLOGY, 2020, 22 : 79 - 79
  • [8] Outcomes of ALK plus non-small cell lung cancer (NSCLC) patients treated with ALK inhibitors in the clinical trial setting and in a referral Institution.
    Rojo, Ana Matres
    Felip, Enriqueta
    Dienstmann, Rodrigo
    Garces, Victor Navarro
    Viaplana, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Brain metastases and mortality in patients with ALK plus metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
    Uprety, Dipesh
    Abrahami, Devin
    Marcum, Zachary A.
    Li, Benjamin
    Sang, Angela
    Davis, Matthew
    Rifi, Nada
    Kelton, John M.
    Ramaswamy, Krishnan
    Sanghvi, Parag
    Bazhenova, Lyudmila
    LUNG CANCER, 2025, 201
  • [10] Indirect Naive Comparison of ALK Inhibitors for ALK plus Non-Small Cell Lung Cancer (NSCLC) Post-Crizotinib Failure
    Reckamp, Karen L.
    Huang, Joice
    Huang, Hui
    Moore, Yan
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S313 - S314
12345